JP2001505194A - 分枝ペプチド・リンカー - Google Patents

分枝ペプチド・リンカー

Info

Publication number
JP2001505194A
JP2001505194A JP52160698A JP52160698A JP2001505194A JP 2001505194 A JP2001505194 A JP 2001505194A JP 52160698 A JP52160698 A JP 52160698A JP 52160698 A JP52160698 A JP 52160698A JP 2001505194 A JP2001505194 A JP 2001505194A
Authority
JP
Japan
Prior art keywords
group
formula
compound according
defined above
lys
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP52160698A
Other languages
English (en)
Japanese (ja)
Inventor
キング，ダルトン
ファイアストーン，レイモンド・エイ
デゥボーチック，ジーン・エム
Original Assignee
ブリストル―マイヤーズ・スクイブ・カンパニー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ブリストル―マイヤーズ・スクイブ・カンパニー filed Critical ブリストル―マイヤーズ・スクイブ・カンパニー
Publication of JP2001505194A publication Critical patent/JP2001505194A/ja
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06086—Dipeptides with the first amino acid being basic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/641—Branched, dendritic or hypercomb peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06052—Val-amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
JP52160698A 1996-11-05 1997-10-31 分枝ペプチド・リンカー Ceased JP2001505194A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3036796P 1996-11-05 1996-11-05
US60/030,367 1996-11-05
PCT/US1997/019851 WO1998019705A1 (fr) 1996-11-05 1997-10-31 Sequences de liaison peptidiques ramifiees

Publications (1)

Publication Number Publication Date
JP2001505194A true JP2001505194A (ja) 2001-04-17

Family

ID=21853889

Family Applications (1)

Application Number Title Priority Date Filing Date
JP52160698A Ceased JP2001505194A (ja) 1996-11-05 1997-10-31 分枝ペプチド・リンカー

Country Status (5)

Country Link
EP (1) EP0941120A4 (fr)
JP (1) JP2001505194A (fr)
AU (1) AU5159798A (fr)
CA (1) CA2264610A1 (fr)
WO (1) WO1998019705A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007501014A (ja) * 2003-08-05 2007-01-25 ウイスコンシン アラムニ リサーチ ファンデーション 化学療法剤の送達のための標的化されたキャリア融合物
JP4560210B2 (ja) * 1998-05-22 2010-10-13 第一三共株式会社 薬物複合体
JP2017503011A (ja) * 2013-12-16 2017-01-26 ジェネンテック， インコーポレイテッド ペプチド模倣化合物及びその抗体−薬物コンジュゲート
WO2022255425A1 (fr) * 2021-06-01 2022-12-08 味の素株式会社 Conjugué d'un anticorps et d'une substance fonctionnelle ou d'un sel dudit conjugué, et composé à utiliser dans la production dudit conjugué ou sel dudit composé

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998013059A1 (fr) * 1996-09-27 1998-04-02 Bristol-Myers Squibb Company Promedicaments hydrolysables pour la liberation de medicaments anticancereux dans des cellules metastatiques
US6264917B1 (en) 1996-10-28 2001-07-24 Nycomed Imaging As Targeted ultrasound contrast agents
US6331289B1 (en) 1996-10-28 2001-12-18 Nycomed Imaging As Targeted diagnostic/therapeutic agents having more than one different vectors
US6261537B1 (en) 1996-10-28 2001-07-17 Nycomed Imaging As Diagnostic/therapeutic agents having microbubbles coupled to one or more vectors
US6545125B1 (en) * 1997-11-18 2003-04-08 Chugai Seiyaku Kabushiki Kaisha Compounds with antitumor activity
AU765409B2 (en) 1998-10-30 2003-09-18 Daiichi Pharmaceutical Co., Ltd. DDS compounds and method for assaying the same
US6191290B1 (en) * 1999-02-24 2001-02-20 Uab Research Foundation Taxane derivatives for targeted therapy of cancer
EP1176985A2 (fr) * 1999-04-28 2002-02-06 Vectramed, Inc. Conjugues de medicaments polymeres actives par voie enzymatique
ATE349438T1 (de) 1999-11-24 2007-01-15 Immunogen Inc Cytotoxische wirkstoffe enthaltend taxane und deren therapeutische anwendung
DE10048417A1 (de) * 2000-09-29 2002-04-11 Roche Diagnostics Gmbh Verbindungen mit verzweigtem Linker
JP2004528309A (ja) 2001-03-23 2004-09-16 ナプロ バイオセラピューティクス，インコーポレイテッド 癌治療用分子複合体
JP4342314B2 (ja) * 2001-12-17 2009-10-14 ユニバーシティ カレッジ カーディフ コンサルタンツ リミテッド 病変部位への特異的送達のための開裂薬剤
CN100522955C (zh) 2002-08-02 2009-08-05 伊缪诺金公司 含有新型强效紫杉烷的细胞毒性剂及其治疗用途
US7390898B2 (en) 2002-08-02 2008-06-24 Immunogen Inc. Cytotoxic agents containing novel potent taxanes and their therapeutic use
AU2003256038A1 (en) * 2002-08-30 2004-03-19 Ramot At Tel Aviv University Ltd. Self-immolative dendrimers releasing many active moieties upon a single activating event
AU2003282624A1 (en) 2002-11-14 2004-06-03 Syntarga B.V. Prodrugs built as multiple self-elimination-release spacers
US6906158B2 (en) 2003-03-13 2005-06-14 Irm, Llc Compositions and methods of vinyl oxazolone polymerization
US20040228831A1 (en) * 2003-05-15 2004-11-18 Belinka Benjamin A. Polymeric conjugates for tissue activated drug delivery
ES2408704T3 (es) 2005-01-05 2013-06-21 Biogen Idec Ma Inc. Moléculas de unión a Cripto
MX2009003548A (es) * 2006-10-03 2009-04-15 Alnylam Pharmaceuticals Inc Formulaciones que contienen lipidos.
US9738707B2 (en) 2011-07-15 2017-08-22 Biogen Ma Inc. Heterodimeric Fc regions, binding molecules comprising same, and methods relating thereto
PL2802606T3 (pl) 2012-01-10 2018-09-28 Biogen Ma Inc. Udoskonalenie transportu cząsteczek terapeutycznych przez barierę krew-mózg
WO2014194030A2 (fr) * 2013-05-31 2014-12-04 Immunogen, Inc. Conjugués comprenant des agents de liaison cellulaire et des agents cytotoxiques
MX2016007826A (es) 2013-12-16 2017-03-31 Genentech Inc Compuestos peptidomimeticos y sus conjugados de anticuerpo-farmaco.
US10933112B2 (en) * 2014-02-17 2021-03-02 Seagen Inc. Hydrophilic antibody-drug conjugates
US10533059B2 (en) * 2014-03-12 2020-01-14 Akamara Therapeutics, Inc. Targeted drug delivery through affinity based linkers
KR101628872B1 (ko) 2014-05-28 2016-06-09 주식회사 레고켐 바이오사이언스 자가-희생 기를 포함하는 화합물
WO2016205176A1 (fr) 2015-06-15 2016-12-22 Genentech, Inc. Anticorps et immunoconjugués
EP3380126A4 (fr) * 2015-11-25 2019-07-24 LegoChem Biosciences, Inc. Conjugués anticorps-médicament comprenant des lieurs ramifiés et procédés connexes
CA3006247A1 (fr) 2015-11-25 2017-06-01 Legochem Biosciences, Inc. Conjugues comprenant des groupes peptidiques et procedes associes a ceux-ci
US11413353B2 (en) 2015-11-25 2022-08-16 Legochem Biosciences, Inc. Conjugates comprising self-immolative groups and methods related thereto
CA3058360A1 (fr) 2017-03-29 2018-10-04 Legochem Biosciences, Inc. Promedicament de dimere de pyrrolobenzodiazepine et son compose de conjugue ligand-lieur
EP3755707A1 (fr) 2018-02-20 2020-12-30 Seagen Inc. Composés d'auristatine f hydrophobes et conjugués de ceux-ci
MX2020011554A (es) 2018-05-09 2020-11-24 Legochem Biosciences Inc Composiciones y metodos relacionados con conjugados de farmacos de anticuerpo anti grupo de diferenciacion 19 (cd19).
KR20210028544A (ko) 2019-09-04 2021-03-12 주식회사 레고켐 바이오사이언스 인간 ror1에 대한 항체를 포함하는 항체 약물 접합체 및 이의 용도
MX2023001466A (es) 2020-08-03 2023-03-03 Bicycletx Ltd Enlazadores de base peptidica.
WO2022069461A1 (fr) 2020-09-30 2022-04-07 F. Hoffmann-La Roche Ag Complexes protéiques stabilisés fimgt-dsf de pilus bactériens pour la production de phages filamenteux

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5084560A (en) * 1986-06-30 1992-01-28 Oncogen Immunoconjugates and methods for their use in tumor therapy
US4975278A (en) * 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
US5017693A (en) * 1987-12-02 1991-05-21 Neorx Corporation Methods for introducing a sulfhydryl amino or hydroxyl groups to a compound
US5563250A (en) * 1987-12-02 1996-10-08 Neorx Corporation Cleavable conjugates for the delivery and release of agents in native form
FI102355B1 (fi) * 1988-02-11 1998-11-30 Bristol Myers Squibb Co Menetelmä yhdistävän välikappaleen omaavien antrasykliini-immunokonjugaattien valmistamiseksi
US5252713A (en) * 1988-09-23 1993-10-12 Neorx Corporation Polymeric carriers for non-covalent drug conjugation
US5116944A (en) * 1989-12-29 1992-05-26 Neorx Corporation Conjugates having improved characteristics for in vivo administration
IT1240643B (it) * 1990-05-11 1993-12-17 Mediolanum Farmaceutici Spa Peptidi biologicamente attivi contenenti in catena 2-alchiltriptofano
US5137877B1 (en) * 1990-05-14 1996-01-30 Bristol Myers Squibb Co Bifunctional linking compounds conjugates and methods for their production
ES2118820T3 (es) * 1991-04-05 1998-10-01 Univ Washington Anticuerpos monoclonales para receptores de factores de celulas pluripotentes.
US5622929A (en) * 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
US5443953A (en) * 1993-12-08 1995-08-22 Immunomedics, Inc. Preparation and use of immunoconjugates

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4560210B2 (ja) * 1998-05-22 2010-10-13 第一三共株式会社 薬物複合体
JP2007501014A (ja) * 2003-08-05 2007-01-25 ウイスコンシン アラムニ リサーチ ファンデーション 化学療法剤の送達のための標的化されたキャリア融合物
JP2017503011A (ja) * 2013-12-16 2017-01-26 ジェネンテック， インコーポレイテッド ペプチド模倣化合物及びその抗体−薬物コンジュゲート
WO2022255425A1 (fr) * 2021-06-01 2022-12-08 味の素株式会社 Conjugué d'un anticorps et d'une substance fonctionnelle ou d'un sel dudit conjugué, et composé à utiliser dans la production dudit conjugué ou sel dudit composé

Also Published As

Publication number Publication date
CA2264610A1 (fr) 1998-05-14
EP0941120A1 (fr) 1999-09-15
AU5159798A (en) 1998-05-29
WO1998019705A1 (fr) 1998-05-14
EP0941120A4 (fr) 2004-08-18

Similar Documents

Publication Publication Date Title
JP2001505194A (ja) 分枝ペプチド・リンカー
US6759509B1 (en) Branched peptide linkers
AU687795B2 (en) Lysosomal enzyme-cleavable antitumor drug conjugates
JP2023036868A (ja) クロスリンカーおよびそれらの使用
EP0871490B1 (fr) Segments de liaison hydrazone ramifies
JP3234980B2 (ja) 新規な二官能性化合物を含むコンジュゲートの製法
EP0294294B1 (fr) Dérivés aminés d'antibiotiques du type anthracycline
JP5064037B2 (ja) 複素環式自壊的リンカーおよび結合体
JP7224365B2 (ja) 酸性自己安定化ジョイントを有する抗体薬物複合体
JPH0625012A (ja) チオエーテルコンジュゲート
EP3218391B1 (fr) Analogues de tubulysine et procédés de production et d'utilisation
JPH05501726A (ja) 生物活性剤用新規リンカー
EP4285937A1 (fr) Conjugué et son utilisation
WO2024012566A2 (fr) Anticorps, lieurs, charge utile, conjugués et leurs applications
WO2024012569A1 (fr) Lieurs, conjugués et leurs applications
WO2024078612A1 (fr) Composé de charge utile et de lieur, conjugués et applications associées
WO2024041587A1 (fr) Composition pharmaceutique de conjugué anticorps-médicament

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20040824

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20071204

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20080225

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20080414

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080602

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090901

A313 Final decision of rejection without a dissenting response from the applicant

Free format text: JAPANESE INTERMEDIATE CODE: A313

Effective date: 20091221

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100126